SWK Holdings Corporation (SWKH)

NASDAQ: SWKH · IEX Real-Time Price · USD
17.88
+0.08 (0.45%)
Mar 24, 2023, 4:00 PM EDT - Market closed
0.45%
Market Cap 229.23M
Revenue (ttm) 46.64M
Net Income (ttm) 16.99M
Shares Out 12.82M
EPS (ttm) 1.31
PE Ratio 13.65
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,309
Open 18.09
Previous Close 17.80
Day's Range 17.78 - 18.09
52-Week Range 16.06 - 19.99
Beta 0.33
Analysts Buy
Price Target 26.01 (+45.47%)
Earnings Date May 8, 2023

About SWKH

SWK Holdings Corporation, a specialty finance company that focuses on the healthcare sector. It operates in two segments, Finance Receivables and Pharmaceutical Development. The company provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors. It also offers non-discretionary investment advisory services to institutional clients in separately man... [Read more]

Sector Financials
IPO Date Sep 22, 1999
Employees 33
Stock Exchange NASDAQ
Ticker Symbol SWKH
Full Company Profile

Financial Performance

In 2021, SWK Holdings's revenue was $56.16 million, an increase of 52.96% compared to the previous year's $36.71 million. Earnings were $25.93 million, an increase of 398.44%.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for SWKH stock is "Buy." The 12-month stock price forecast is $26.01, which is an increase of 45.47% from the latest price.

Price Target
$26.01
(45.47% upside)
Analyst Consensus: Buy
Stock Forecasts

News

SWK Holdings Appoints Jerry Albright to Board of Directors

DALLAS , March 15, 2023 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-s...

1 week ago - PRNewsWire

SWK Holdings Provides Portfolio Update Highlighting Recent Achievements

Fourth Quarter and Full Year 2022 Financial Results to be Announced in March DALLAS , Jan. 31, 2023 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science-foc...

1 month ago - PRNewsWire

SWK Holdings Names Jody Staggs Chief Executive Officer and Appoints Laurie Dotter as Chair of the Board

Mr. Staggs elevated from "interim" to "permanent" CEO as SWK advances multiple initiatives in 2023 Ms. Dotter joined SWK's Board of Directors in February 2022 DALLAS , Jan. 3, 2023 /PRNewswire/ -- SWK...

2 months ago - PRNewsWire

SWK Holdings Corporation Announces Upsizing of Credit Facility up to $50 Million

DALLAS , Nov. 16, 2022 /PRNewswire/ -- SW K Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-s...

4 months ago - PRNewsWire

SWK Holdings Corporation Announces Financial Results for Third Quarter 2022

Conference Call and Live Audio Webcast Scheduled for Thursday, November 10, 2022, at 10:00 a.m. ET Corporate Highlights Successful leadership transition with Jody Staggs named President and Interim Ch...

Other symbols: AZYO
4 months ago - PRNewsWire

SWK Holdings Corporation to Report Third Quarter 2022 Financial Results

Conference Call and Live Audio Webcast Scheduled for Thursday, November 10, 2022, at 10:00 a.m. ET DALLAS , Nov. 8, 2022 /PRNewswire/ -- SWK Holdings Corporation (NASDAQ: SWKH) ("SWK" or the "Company"...

4 months ago - PRNewsWire

Enteris BioPharma Presents Study of Ovarest® Demonstrating Oral Delivery Comparable to or Exceeding Injectable Leuprolide

Oral Presentation Delivered at the American Society for Reproductive Medicine Scientific (ASRM) 2022 Congress & Expo BOONTON, N.J. , Oct. 26, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnol...

5 months ago - PRNewsWire

SWK Holdings' Subsidiary, Enteris BioPharma, Receives $5 Million Milestone Payment from Cara Therapeutics

Milestone payment highlights ongoing clinical progress of Oral KORSUVA™ DALLAS , Oct. 10 2022  /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance compan...

Other symbols: CARA
5 months ago - PRNewsWire

SWK Holdings Enhances Executive Management Team and Expands Underwriting Team

Yvette Heinrichson promoted to Chief Financial Officer John David Tamas promoted to Director of Underwriting DALLAS , Oct. 3, 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the...

6 months ago - PRNewsWire

Enteris BioPharma Publishes White Paper Examining Factors to Consider While Evaluating Oral Administration of Peptides

Physicochemical properties of peptides can provide key insights to potential success of oral delivery BOONTON, N.J. , Sept. 12, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company de...

6 months ago - PRNewsWire

SWK Holdings to Participate in Lake Street Capital's 6th Annual Best Ideas Growth Conference "BIG6"

DALLAS , Sept. 7, 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-st...

7 months ago - PRNewsWire

SWK Holdings Announces Leadership Transition

Jody Staggs appointed as President and Interim CEO CEO Winston Black will assist in an interim consulting role after successfully establishing SWK Holdings as a leading life science focused specialty ...

7 months ago - PRNewsWire

SWK Holdings Corporation Announces Financial Results for Second Quarter 2022

Conference Call and Live Audio Webcast Scheduled for Thursday, August 11, 2022, at 10:00 a.m. ET Corporate Highlights Celebrated 10th anniversary as a life science focused specialty finance company ca...

8 months ago - PRNewsWire

SWK Holdings Corporation to Report Second Quarter 2022 Financial Results

Conference Call and Live Audio Webcast Scheduled for Thursday, August 11, 2022, at 10:00 a.m. ET DALLAS , Aug. 9, 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"),...

8 months ago - PRNewsWire

Enteris BioPharma Manufacturing Expertise Highlighted in Drug Development & Delivery Special Feature on Outsourcing Formulation Development & Manufacturing

Article describes Enteris' strengths and scalability in working with highly potent active pharmaceutical ingredients BOONTON, N.J. , August 3, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechno...

8 months ago - PRNewsWire

Enteris BioPharma Announces Acceptance of Abstract for Oral Presentation at ASRM 2022 Scientific Congress & Expo

BOONTON, N.J. , July 14, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned su...

9 months ago - PRNewsWire

SWK Holdings Corporation Marks 10th Anniversary, Celebrating Growth and Progress

Since 2012, SWK Holdings has completed financings with 46 life sciences companies, deploying $650 million of capital Second Quarter 2022 Financial Results to be Announced in August DALLAS , July 13, 2...

9 months ago - PRNewsWire

SWK Holdings Corporation Added to Russell 3000® Index, Russell 2000® Index and Russell Microcap® Index

DALLAS , June 27, 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH), a life science-focused specialty finance company catering to small-and mid-sized commercial-stage companies, announced t...

9 months ago - PRNewsWire

Enteris BioPharma Presents Data from Two Clinical Studies Involving Oral Formulations of Leuprolide at ENDO 2022 Annual Conference

Data suggest that oral formulations of leuprolide developed utilizing Enteris' Peptelligence® platform successfully deliver meaningful circulating drug concentrations and achieve hormonal suppressive ...

10 months ago - PRNewsWire

Enteris BioPharma Publishes White Paper Examining Safe Handling and Manufacture of Highly Potent Active Pharmaceutical Ingredients (HPAPI)

Facilities and processes key to protecting workers and the environment, the paper in Drug Development & Delivery says BOONTON, N.J. , June 7, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnol...

10 months ago - PRNewsWire

Enteris Employees Lend Ronald McDonald House a Helping Hand at Enteris Day 2022

BOONTON, N.J. , May 26, 2022 /PRNewswire/ --  Enteris BioPharma, Inc. gave plush animals a dose of personality as they created a dozen stuffed teddy bears for Ronald McDonald House Charities to help c...

10 months ago - PRNewsWire

SWK Holdings Corporation Announces Filing of Form S-3 Shelf Registration Statement

Authorizes 10b5-1 Stock Repurchase Program DALLAS , May 19, 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company cate...

11 months ago - PRNewsWire

SWK Holdings Corporation Announces Financial Results for First Quarter 2022

Conference Call and Live Audio Webcast Scheduled for Wednesday, May 11, 2022, at 10:00 a.m. ET Corporate Highlights During first quarter of 2022, completed two structured debt transactions deploying $...

11 months ago - PRNewsWire

SWK Holdings Corporation to Report First Quarter 2022 Financial Results

Conference Call and Live Audio Webcast Scheduled for Wednesday, May 11, 2022, at 10:00 a.m. ET DALLAS , May 10, 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a...

11 months ago - PRNewsWire

Enteris BioPharma to Exhibit at CPhI North America 2022

BOONTON, N.J. , May 4, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subs...

11 months ago - PRNewsWire